Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Adenosine A1 receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The adenosine A₁ receptor is one member of the adenosine receptor group of G protein-coupled receptors with adenosine as endogenous ligand.
Compositions & formulations with an epiandrosterone or a ubiquinone & kits & their use for treatment of asthma symptoms & for reducing adenosine/adenosine receptor levels
A composition and various formulations comprise preventative or therapeutic amounts of an epiandrosterone, analogue thereof or salt thereof, and / or a ubiquinone or salt thereof, and a pharmaceutically or veterinarily acceptable carrier or diluent. The composition and formulations are useful for treating bronchoconstriction, respiratory tract inflammation and allergies, asthma, and cancer. A method of treating diseases associated with low adenosine levels or adenosine depletion comprises administering folinic acid or a pharmaceutically acceptable salt hereof in a preventative or therapeutic amount, or an amount effective to treat adenosine depletion.
Owner:EAST CAROLINA UNIVERISTY
Oxidated derivatives of triazolylpurines useful as ligands of the adenosine A2A receptor and their use as medicaments
Owner:ALFASIGMA SPA
Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening
ActiveUS20090123510A1Potential damageEliminate side effectsBiocideSugar derivativesProsthesisAdenosine a
The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adenosine A2A receptor, in particular, an agonist of an adenosine A2A receptor. The invention also extends to pharmaceutical compositions comprising such an agent that modulates an adenosine receptor such as an adenosine A2A agonist and to prosthetic devices containing such an agent that modulates an adenosine receptor such as an A2A agonist on one or more surfaces or within the prosthetic device such as, for example, suspended in the cement forming the prosthetic device.
Owner:NEW YORK UNIV
Partial and full agonists of A1 adenosine receptors
InactiveUS6946449B2Avoid actionMaintain liquidityBiocideSugar derivativesAnginaAdenosine A1 receptor
Disclosed are novel compounds that are partial and full A1 adenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.
Owner:GILEAD SCI INC
Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
InactiveUS7064112B1Prevent proliferationInhibit proliferation and growth of tumor cellBiocideSugar derivativesSide effectLeukopenia
Owner:CAN-FITE BIOPHARMA LTD
Pharmaceutical administration of adenosine agonists
InactiveUS6638914B1Increase the molecule's A.sub.1 selectivityImprove biological activityBiocideSugar derivativesBone marrow cellBone marrow cell proliferation
The present invention relates to pharmaceutical compositions for use in inducing proliferation of the hematopoietic system, in particular, of bone marrow cells, comprising a pharmaceutically acceptable carrier, excipient or diluent and, as an active ingredient, an effective amount of an adenosine A1 receptor agonist. The pharmaceutical composition of the present invention may be used to induce proliferation of bone marrow cells, in a variety of clinical situations where such proliferation is therapeutically beneficial.The active ingredient within the pharmaceutical composition of the invention may be a compound of general formula (I) as described herein or any other compound or substance which specifically binds to and / or activates the A1 adenosine receptor and acts as an agonist to the receptor's natural ligand.
Owner:CAN-FITE BIOPHARMA LTD
A3 adenosine receptor ligands for modulation of pigmentation
ActiveUS20120134945A1Treating and ameliorating skinTreating and ameliorating skin hypo-pigmentationBiocideCosmetic preparationsAdenosine A1 receptorA3 adenosine receptor ligand
The present invention relates to compositions and methods for modulating melanin production, secretion and / or accumulation in human skin cells. In particular, the present invention relates to the use of A3 adenosine receptor antagonists in compositions and methods for the treatment and amelioration of hyper-pigmentation conditions and for the lightening of skin, and to the use of A3 adenosine receptor agonists in compositions and methods for the treatment and amelioration of hypo-pigmentation conditions and for the tanning of skin.
Owner:ORADIN PHARMA
Antagonizing an adenosine A2A receptor to ameliorate one or more components of addictive behavior
InactiveUS20060128708A1Many componentReduce the impactBiocideNervous disorderAddictive behaviorAdenosine A2A Receptor Antagonists
This invention provides a method of mitigating / ameliorating one or more components of addictive behavior associated with chronic consumption of a substance of abuse, or withdrawal therefrom. The method typically involves administering to a subject in need thereof an adenosine A2A receptor antagonist in an amount sufficient to ameliorate said one or more components of addictive behavior.
Owner:RGT UNIV OF CALIFORNIA
A3 adenosine receptor agonists and antagonists
Disclosed are (N)-methanocarba adenine nucleosides of formulas (I)-(V), for example, of formula (V):as highly potent A3 adenosine receptor agonists, pharmaceutical compositions comprising such nucleosides, and a method of use of these nucleosides, wherein R1-R6 are as defined in the specification. These nucleosides exhibit similar selectivities as agonists of the A3 versus the A1 receptor for both human and mouse adenosine receptors, and are contemplated for use in the treatment a number of diseases, for example, inflammation, cardiac ischemia, stroke, asthma, diabetes, and cardiac arrhythmias.
Owner:US DEPT OF HEALTH & HUMAN SERVICES
Substituted 8-[6-amino-3-pyridyl]xanthines
The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.
![Substituted 8-[6-amino-3-pyridyl]xanthines](https://images-eureka.patsnap.com/patent_img/20ba0475-c048-43a3-a7d0-5c1aeb5e26d0/US20080004292A1-20080103-C00001.png "Substituted 8-[6-amino-3-pyridyl]xanthines")
![Substituted 8-[6-amino-3-pyridyl]xanthines](https://images-eureka.patsnap.com/patent_img/20ba0475-c048-43a3-a7d0-5c1aeb5e26d0/US20080004292A1-20080103-C00002.png "Substituted 8-[6-amino-3-pyridyl]xanthines")
![Substituted 8-[6-amino-3-pyridyl]xanthines](https://images-eureka.patsnap.com/patent_img/20ba0475-c048-43a3-a7d0-5c1aeb5e26d0/US20080004292A1-20080103-C00003.png "Substituted 8-[6-amino-3-pyridyl]xanthines")
Owner:ALLERGAN SALES LLC
Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
InactiveUS20070191279A1Reduce the total massBiocidePeptide/protein ingredientsCompound (substance)Surgery
The invention provides methods and compositions for modulating osteoclastogenesis and for treating bone diseases characterized by bone loss or a decrease in bone mass or density, by administering a compound or agent that modulates the adenosine A1 receptor, in particular, an inhibitor or antagonist of the A1 receptor.
Owner:NEW YORK UNIV
RNA Interference Mediated Inhibition of Adenosine A1 Receptor (ADORA1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
InactiveUS20090247606A1Preserve activityImprove compound stabilitySenses disorderNervous disorderFhit geneSmall interfering RNA
The present invention concerns methods and reagents useful in modulating adenosine A1 receptor (ADORA1) gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small interfering RNA (siRNA) molecules capable of mediating RNA interference (RNAi) against ADORA1 and related receptors.
Owner:SIRNA THERAPEUTICS INC
Use of adenosine receptor signaling to modulate permeability of blood-brain barrier
InactiveUS20130224110A1Permeability of BBB is increasedFacilitates CNS entryBiocideHeavy metal active ingredientsMedicineBbb permeability
The present invention relates to a method of increasing blood brain barrier (“BBB”) permeability in a subject. This method involves administering to the subject an agent or agents which activate both of the A1 and A2A adenosine receptors. Also disclosed is a method to decrease BBB permeability in a subject. This method includes administering to the subject an agent which inhibits or blocks the A2A adenosine receptor signaling. Compositions relating to the same are also disclosed.
Owner:CORNELL UNIVERSITY
A3 adenosine receptors as targets for the modulation of central serotonergic signaling
InactiveUS20090088403A1Reducing SERT activityEnhance SERT activityBiocideCarbohydrate active ingredientsSerotonin transporterIn vivo
The present invention relates to the use of adenosine type 3 receptor (A3R) modulators to modulate serotonin transporter (SERT) function in vivo. In particular, antagonists of A3R can be used to inhibit A3R-dependent upregulation of SERT, for example, as antidepressants.
Owner:VANDERBILT UNIV
Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
ActiveUS20080176845A1Inhibits cytokine levelIncreased proliferationBiocideDigestive systemAdenosine A1 receptorEnteropathy
The present invention relates to method for treating inflammatory bowel disease that includes administration of an effective amount of an antagonist of A2B adenosine receptors (ARs).
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND +1
Adenosine receptor stimulating agent and application thereof
The invention relates to an application HEA of N (6)-(2-hydroxyethyl)-adenosine (HEA) and derivatives thereof in medicine or food preparation as an adenosine A1 receptor stimulating agent as well as an application of the derivatives thereof in treating nervous system diseases, such as calming and hypnotizing, anti-convulsion, cerebral protection, Parkinson disease, drug addiction and the like, related to an adenosine receptor conditioner. The invention offers a new drug source for the prevention of nervous system diseases.
Owner:ZHEJIANG CHENGYI PAHRMACEUTICAL
Purine derivatives as A3 adenosine receptor-selective agonists
Owner:UNITED STATES OF AMERICA
Therapeutic agent for migraine
Owner:KYOWA HAKKO KIRIN CO LTD
Purine derivatives as adenosine A1 receptor agonists and methods of use thereof
InactiveUS20050282768A1Reduction in rate of metabolismAntibacterial agentsBiocideReperfusion injuryPurine
The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.
Owner:INOTECK PHARMA CORP
Method of identifying partial adenosine A1 receptor agonists and their use in the treatment of arrhythmias
InactiveUS20010008883A1Guaranteed predictive effectBiocideSugar derivativesIntensive care medicineAdenosine A1 receptor
Owner:CV THERAPEUTICS INC
Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
ActiveUS10196396B2Preventing and ameliorating and treating glaucomaBiocideSenses disorderDiseaseGlaucoma
Owner:HANDOK INC
Compounds specific to adenosine A, receptors and uses thereof
Owner:OSI PHARMA INC
New compounds as adenosine a1 receptor antagonists
This compounds correspond to the formula (I), where: R1 represents and aryl or heteroaryl group optionally substituted by one or more substituents selected from the group consisting of halogen atoms, straight or branched optionally substituted lower alkyl, cycloalkyl, hydroxy, straight or branched, optionally substituted lower alkoxy, cyano, or -CO2R', wherein R' represents a hydrogen atom or a straight or branched, optionally substituted lower alkyl group; R2 represents a group selected from: a) a straight or branched lower alkyl group substituted by one or more carboxylic groups (-COOH) andoptionally substituted by one or more halogen atoms; b) a cycloalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms; c) a straight or branched alkylcycloalkyl or cycloalkylalkyl group substituted by one or more carboxylic groups (-COOH) and optionally substituted by one or more halogen atoms.
Owner:PALOBIOFARMA SL
Small-molecular antagonist for A3 adenosine receptor
ActiveCN108017584AOrganic active ingredientsSenses disorderAdenosine A1 receptorAdenosine A2A receptor
The invention discloses a small-molecular antagonist for an A3 adenosine receptor, and an application thereof in medicine synthesis, and concretely relates to a use of the small-molecular antagonist for the A3 adenosine receptor and pharmacologically available salts of the small-molecular antagonist for the A3 adenosine receptor as medicines for treating or preventing A3 adenosine receptor-mediated related diseases or symptoms.
Owner:NANKAI UNIV
Cordycepin-containing composition and application thereof
InactiveCN108272814AWide variety of sourcesPrevention/Treatment of AbnormalitiesOrganic active ingredientsCosmetic preparationsCoronary heart diseaseBiology
The invention provides a cordycepin-containing composition, and belongs to the field of traditional Chinese medicine preparations. The cordycepin-containing composition is prepared from the followingraw materials in parts by weight: 0.1 to 3 parts of cordycepin and 1 to 12 parts of nuciferine. The cordycepin-containing composition provided by the invention is simple in compatibility, the source of raw materials is wide, accumulation of white fat and the contents of serum TC (Total Cholesterol), TG (Triglyceride) and LDL (Low-Density Lipoprotein) can be remarkably reduced, the content of HDL (High-Density Lipoprotein) can be remarkably increased, the protein level of a adenosine A1 receptor of a GH3 cell can be induced to be increased, and lactation release of the GH3 cell can be remarkably inhibited; visually, the cordycepin-containing composition provided by the invention is capable of preventing obesity, losing weight, preventing / treating hyperlipidemia, conditioning lipoprotein abnormality, conditioning lipid metabolism and reducing an occurrence rate of a coronary heart disease at the same time.
Owner:SHENZHEN SUNNY BIO TECH CO LTD
Therapeutic agent for migraine
Provided are therapeutic and / or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor antagonistic activity or a pharmaceutically acceptable salt thereof; therapeutic and / or preventive agents for migraine which comprise, as an active ingredient, a compound having a selective adenosine A2A receptor antagonistic activity, which has an affinity for the adenosine A2A receptor 10 times or higher than that for the adenosine A1 receptor, or a pharmaceutically acceptable salt thereof; and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Pharmaceutical use of adenosine agonists
InactiveUS20020037871A1High selectivityImprove biological activityBiocideCarbohydrate active ingredientsBone marrow cellBULK ACTIVE INGREDIENT
The present invention relates to a method for inducing proliferation of the hematopoietic system, in particular, of bone marrow cells, comprising administering to a subject an effective amount of an adenosine A1 receptor agonist. The method of the invention may be utilized n a variety of clinical situations where such proliferation is therapeutically beneficial. The active ingredient within the pharmaceutical composition of the invention may be a compound of general formula (I) as described herein, or any other compound or substance which specifically binds to and / or activates the A1 adenosine receptor and acts as an agonist to the receptor's natural ligand.
Owner:CAN-FITE BIOPHARMA LTD
Pharmaceutical use of adenosine agonists
InactiveUS20010031742A1High selectivityImprove biological activityBiocideCarbohydrate active ingredientsWhite blood cellBone marrow cell
The present invention relates to a method of inducing proliferation of bone marrow cells in a subject, compromising administering to the subject an effective amount of an adenosine A1 receptor agonist. The present invention further relates to a method for preventing reduction in level of leukocytes in a subject as a result of a treatment comprising administering to the individual an effective amount of an adenosine A1 receptor agonist. In addition, the invention relates to a method of treatment of an individual comprising administering to the subject a therapeutic drug in combination with an adenosine A1 receptor agonist.
Owner:CAN-FITE BIOPHARMA LTD
Construction and application of adenosine 5'-monophosphate mediated nano transmission system for target tumor
The invention relates to construction and application of adenosine 5'-monophosphate mediated nano transmission system for a target tumor and discloses novel compound adenosine 5'-monophosphate capable of targeting tumor cells. The compound plays the targeting role by identifying adenosine A1 receptors expressed on the surfaces of the tumor cells, can be connected with a few detectable markers such as fluorescent marks for preparation of a targeting tumor diagnosis preparation and can also be connected with a few substances with tumor inhibition activity for preparation of a targeting tumor inhibition preparation.
Owner:EAST CHINA UNIV OF SCI & TECH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com